Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf Wegovy 1.0mg doesn't seem to be working, the most likely explanation is that 1.0mg is not a maintenance dose. It is a mid-titration step, and weight loss at this point is not the measure of whether the treatment will work for you. Most people see meaningful results only once they reach and settle at the 2.4mg maintenance dose, which typically takes around four months from starting. These are prescription-only medicines; whether to continue, adjust or stop is a clinical decision made with your prescriber, not something to judge at an intermediate dose.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The biggest misunderstanding our prescribers hear about Wegovy at this stage is that a slow start at 1.0mg means the medicine isn't going to deliver. It doesn't mean that. The titration schedule (0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, arriving at 2.4mg) exists primarily to give your body time to adjust to semaglutide rather than to produce weight loss at each step. Appetite suppression tends to build gradually, and the effect at 1.0mg is genuinely partial compared with what most people experience at 2.4mg.
The STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average weight reduction — but that was measured across 68 weeks, with participants at the full maintenance dose for most of that period. Judging the medicine at month two or three, while still climbing the dose ladder, is a bit like judging a flight's speed while it's still on the runway. If you're finding 1.0mg underwhelming, that is entirely expected, and if you're wondering whether your experience signals a wider problem, our guide for people who feel Wegovy isn't working for them is a useful place to start. The question of what comes next belongs with your prescriber.
If you want a broader grounding in how the medicine works before your next review, the Wegovy treatment overview covers the mechanism and what the evidence shows across the full dose range.
There are a few things happening at 1.0mg that can make progress feel slower than expected. First, GLP-1 medicines lower appetite rather than switching it off entirely, and that effect intensifies with dose. At 1.0mg, some people notice only modest appetite changes, especially if they are newer to semaglutide.
Second, the body's response to a calorie deficit is not linear. A common pattern (and one that is not specific to Wegovy) is an initial small drop in weight, then a plateau before the next dose increase restarts progress. That plateau feels like failure when it is actually physiology.
Third, variables outside the medicine matter more than people expect. Poor sleep elevates the hormones that drive hunger. High stress raises cortisol, which promotes fat retention particularly around the abdomen. Low protein intake means the body is more likely to lose muscle alongside fat, which slows metabolic rate. None of these factors mean the medicine is wrong for you; they mean the clinical picture is more than a number on a pen.
Questions about what influences your own response are worth raising at your next clinical check-in. Our clinical team reviews progress at every stage, and that review is where individual factors can be properly weighed. If you are unsure whether your experience is within the normal range, the broader guide to Wegovy not working walks through the most common reasons progress stalls.
There is no reliable shortcut to speeding up the titration schedule, the pacing exists for safety and tolerability. But there are things that genuinely support whatever the medicine is doing, even at 1.0mg.
Protein is the most consistently useful lever. Eating enough protein at each meal (roughly 25–30g per sitting is a widely used clinical benchmark, though personal targets vary) helps preserve muscle mass, keeps you fuller for longer, and works alongside the appetite effects of semaglutide rather than against them. Hydration matters too, particularly since gastrointestinal side effects at this stage can quietly reduce how much people drink.
It is also worth checking the basics around injection technique. Injecting into the same small spot repeatedly can create scar tissue that slows absorption. Rotating between the abdomen, thigh and upper arm with each weekly dose is the standard approach, and the NHS semaglutide medicines page covers technique points worth revisiting.
For context on how long the medicine typically takes to produce visible results, how long Wegovy takes to work sets realistic timeframes based on where you are in the dose schedule. And if you have reached 1.0mg after previously finding a lower dose difficult, the experiences people have at the 0.5mg step are covered separately in what happens when 0.5mg Wegovy doesn't seem to work.
Understanding how cost fits into longer-term planning is something many people find useful at this point too. Treatment pricing and what's included in a private prescription are explained on the weight-loss treatment overview.
Most experiences at 1.0mg that feel like the medicine not working are simply the dose doing its preparatory job. There are situations, though, where getting in touch before your planned review is the right call.
If side effects are severe enough to be disrupting daily life (persistent nausea that isn't settling, significant vomiting or diarrhoea) your prescriber may recommend holding the current dose for longer before increasing rather than pushing through discomfort. Slowing the titration is a recognised clinical option, not a setback. The guide to why Wegovy may not be working covers how prescribers think through those decisions.
Severe stomach pain, particularly pain that spreads to the back, warrants urgent medical attention rather than a message to your prescriber, that presentation needs to be assessed promptly in person. The MHRA has highlighted this as a symptom to take seriously, and it should not be left until a scheduled review.
If you have been taking Wegovy consistently at 1.0mg and feel your concerns are not being heard, that is worth raising directly with whoever is managing your treatment. At nume, aftercare is available seven days a week. Reach out via the support page if you have questions between reviews.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.